[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014CN02022A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02022A
IN2014CN02022A IN2022CHN2014A IN2014CN02022A IN 2014CN02022 A IN2014CN02022 A IN 2014CN02022A IN 2022CHN2014 A IN2022CHN2014 A IN 2022CHN2014A IN 2014CN02022 A IN2014CN02022 A IN 2014CN02022A
Authority
IN
India
Prior art keywords
present
crystal
acid
relates
salts
Prior art date
Application number
Inventor
Jianfeng Li
Guanghui Tian
Zhen Wang
Jin Suo
Xiangrui Jiang
Zheng Liu
Xiaojun Yang
Zhu Xie
Xianguo Zhao
Weiliang Zhu
Hualiang Jiang
Jingshan Shen
Original Assignee
Topharman Shanghai Co Ltd
Shanghai Inst Materia Medica
Topharman Shandong Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topharman Shanghai Co Ltd, Shanghai Inst Materia Medica, Topharman Shandong Co Ltd filed Critical Topharman Shanghai Co Ltd
Publication of IN2014CN02022A publication Critical patent/IN2014CN02022A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to salts and a pharmaceutically acceptable polymorph solvate hydrate dehydrate co crystal anhydride or amorphous form of a novel pyrazolopyrimidinone compound as shown in general formula (I) and to a pharmaceutical composition and a pharmaceutical unit dosage form comprising same wherein X represents an organic or inorganic acid preferably maleic acid succinic acid hydrochloric acid methylsulfonic acid and the like. The present invention further relates to a co crystal or a composite of the pyrazolopyrimidinone compound and a pharmaceutical composition comprising same. The present invention also relates to a preparation method of the abovementioned substances and the use thereof and pharmaceutical preparations comprising these salts and crystal forms.
IN2022CHN2014 2011-08-17 2012-08-14 IN2014CN02022A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110236585.3A CN102952138B (en) 2011-08-17 2011-08-17 The salt of a kind of pyrazolopyrimidinone compound, polymorph and pharmaceutical composition, preparation method and application
PCT/CN2012/001082 WO2013023439A1 (en) 2011-08-17 2012-08-14 Salt and polymorph of pyrazolopyrimidinone compound and drug composition, preparation method and use thereof

Publications (1)

Publication Number Publication Date
IN2014CN02022A true IN2014CN02022A (en) 2015-05-29

Family

ID=47714726

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2022CHN2014 IN2014CN02022A (en) 2011-08-17 2012-08-14

Country Status (13)

Country Link
US (1) US9527849B2 (en)
EP (1) EP2746284B1 (en)
JP (1) JP2014521729A (en)
KR (1) KR20140059241A (en)
CN (1) CN102952138B (en)
AU (1) AU2012297498A1 (en)
BR (1) BR112014003696A2 (en)
CA (1) CA2845250A1 (en)
EA (1) EA201490464A1 (en)
IL (1) IL230907A0 (en)
IN (1) IN2014CN02022A (en)
MX (1) MX2014001756A (en)
WO (1) WO2013023439A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104129803A (en) * 2014-08-12 2014-11-05 天津市嵩锐医药科技有限公司 Stable sodium nitroprusside crystal compound, pharmaceutical composition and preparation method thereof
CN105055336A (en) * 2015-09-24 2015-11-18 青岛华之草医药科技有限公司 Sildenafil citrate composition granules for treating urologic diseases
CN113493459B (en) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 PDE5 inhibitor compound, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832460A (en) * 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6624138B1 (en) * 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
KR100353014B1 (en) * 1998-11-11 2002-09-18 동아제약 주식회사 Pyrazolopyrimidinone derivatives for the treatment of impotence
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
WO2006120552A2 (en) * 2005-05-12 2006-11-16 Pfizer Inc. ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
JP5227178B2 (en) * 2005-11-08 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド N- (5-Chloro-2-pyridinyl) -2-[[4-[(dimethylamino) iminomethyl] benzoyl] amino] -5-methoxy-benzamide, pharmaceutical salts and polymorphs of factor Xa inhibitors
CN1966506A (en) * 2005-11-17 2007-05-23 上海特化医药科技有限公司 Pyrromonazole pyrimidinone derivatives, method of producing them and use thereof
KR101071877B1 (en) * 2009-02-18 2011-10-10 동아제약주식회사 Acid salt of Udenafil, Preparation process thereof and Phamaceutical composition comprising the same
CN101671338B (en) * 2009-09-27 2012-07-25 刘桂坤 Citric acid alidenafil crystal form D and preparation method and usage thereof
CN101691372B (en) * 2009-09-27 2011-11-23 刘桂坤 Aildenafil citrate crystal form C and preparation method and application thereof
CN101671339B (en) * 2009-09-27 2012-06-27 刘桂坤 Citric acid alidenafil crystal form B and preparation method and usage thereof
CN101671337B (en) * 2009-09-27 2011-08-10 刘桂坤 Citric acid aildenafil crystal form A and preparation method and usage thereof
CN102001045B (en) * 2010-10-20 2012-05-30 无锡富岛精工有限公司 Crawler-type sand blasting cleaner

Also Published As

Publication number Publication date
WO2013023439A1 (en) 2013-02-21
EP2746284B1 (en) 2017-04-12
EP2746284A4 (en) 2015-01-14
US9527849B2 (en) 2016-12-27
KR20140059241A (en) 2014-05-15
AU2012297498A1 (en) 2014-04-03
MX2014001756A (en) 2014-09-15
CN102952138A (en) 2013-03-06
US20140309241A1 (en) 2014-10-16
CN102952138B (en) 2016-07-06
EP2746284A1 (en) 2014-06-25
JP2014521729A (en) 2014-08-28
CA2845250A1 (en) 2013-02-21
BR112014003696A2 (en) 2017-06-13
IL230907A0 (en) 2014-03-31
EA201490464A1 (en) 2014-11-28

Similar Documents

Publication Publication Date Title
IN2014MN02106A (en)
UA114906C2 (en) Heterocyclyl compounds
AU2012214029A8 (en) Rorgammat inhibitors
UA108926C2 (en) LibreOfficeKINASE PYRROLO[2,3-DEPENDENT INHIBITORS
TN2011000400A1 (en) Inhibitors of beta-secretase
CA2818187C (en) Bromodomain inhibitors and uses thereof
MY149731A (en) Compounds
MX2016006336A (en) Pyrazolopyrimidine compounds.
PT2323972E (en) C7-fluoro substituted tetracycline compounds
MX345780B (en) Tricyclic gyrase inhibitors.
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2010129057A3 (en) Tetracycline compounds
IN2012DN02502A (en)
MX2008010884A (en) 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carb oxylic acid amides as plk1 inhibitors.
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
WO2010132670A3 (en) Pentacycline compounds
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2013128419A3 (en) Pharmaceutical compositions comprising boronic acid compounds
EA201291014A1 (en) TRICYCLIC INDUSAL COMPOUND, METHOD FOR ITS OBTAINING AND CONTAINING IT PHARMACEUTICAL COMPOSITION
IN2014CN02022A (en)
PL2291374T3 (en) Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
IN2015DN03869A (en)
WO2014106826A3 (en) Anthracycline analogue and uses thereof